Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Multiple myeloma accounts for approximately 10% of hematologic malignancies. The
diagnosis requires≥ 10% clonal bone marrow plasma cells or a biopsy proven …

Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …

Disease overview Multiple myeloma accounts for approximately 10% of hematologic
malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow plasma cells or …

Cancer treatment today employs a combination of chemotherapy, radiotherapy, and surgery
to prolong life and provide cure. However, many of these treatments can cause …

The peripheral nervous system can be vulnerable to the toxic action of several drugs since it
is not protected as effectively as the central nervous system from noxious exogenous agents …

The precise molecular mechanism of action and targets through which thalidomide and
related immunomodulatory drugs (IMiDs) exert their antitumor effects remains unclear. We …

For decades, anticancer targeted therapies have been designed to inhibit kinases or other
enzyme classes and have profoundly benefited many patients. However, novel approaches …

Background High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We
studied whether low-dose dexamethasone in combination with lenalidomide is non-inferior …

The prognosis for patients multiple myeloma (MM) has improved substantially over the past
decade with the development of new, more effective chemotherapeutic agents and regimens …